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Efficient Nuclear Delivery and Nuclear Body Localization of Antisense OligoNucleotides using Degradable Polymersomes
Abstract
Delivery of antisense oligonucleotides, AON, presents many of the same challenges as delivery of any
nucleic acid: charge, stability, cell uptake, endolysosomal escape, and entry into the nucleus. Here we
demonstrate efficient delivery of AON after loading into biodegradable polymer vesicles or
'polymersomes'. We focus on AON delivery to muscle cells in vitro and in vivo because of the emergence
of AON in therapeutic strategies directed at muscular dystrophies. To first clarify uptake kinetics without
the complications of typical multi-layered myotube cultures, we use micro-patterned C2C12 cells and
show efficient uptake of AON-polymersomes. The biodegradable polymersomes break down and foster
AON escape with the binding of fluorescent-AON into the nuclear bodies. Intramuscular injections of the
polymersome-AON into the hind limbs of mdx-dystrophic mice show more efficient nuclear uptake than
AON alone and also lead to dystrophin expression in the mdx mice. In sum, these neutral, degradable
carriers of AON show promise in vivo.
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Efficient Nuclear Delivery and Nuclear Body Localization of
Antisense Oligo-Nucleotides using Degradable Polymersomes
Younghoon Kim1*, Manu Tewari1*, David J. Pajeroski1, Shamik Sen1,
Williams Jason2, Shashank Sirsi2, Gordon Lutz2 and Dennis E. Discher1

Abstract— Delivery of antisense oligonucleotides, AON,
presents many of the same challenges as delivery of any nucleic
acid: charge, stability, cell uptake, endolysosomal escape, and
entry into the nucleus. Here we demonstrate efficient delivery
of AON after loading into biodegradable polymer vesicles or
‘polymersomes’. We focus on AON delivery to muscle cells in
vitro and in vivo because of the emergence of AON in
therapeutic strategies directed at muscular dystrophies. To first
clarify uptake kinetics without the complications of typical
multi-layered myotube cultures, we use micro-patterned C2C12
cells and show efficient uptake of AON-polymersomes. The
biodegradable polymersomes break down and foster AON
escape with the binding of fluorescent-AON into the nuclear
bodies. Intramuscular injections of the polymersome-AON into
the hind limbs of mdx-dystrophic mice show more efficient
nuclear uptake than AON alone and also lead to dystrophin
expression in the mdx mice. In sum, these neutral, degradable
carriers of AON show promise in vivo.

S

Here we detail the AON delivery by controlled-release
polymersomes.
AON
was
encapsulated
within
PBO-PBD/PEO-PCL blend vesicles for programmable
release. The AON delivery into muscle cells for corrective
therapy depends much upon the delivery system that provides
advantages of site-specific delivery, protection from
nucleases and tailored release. PEGylated micelles or
polymersomes have nontoxic, inert properties and cells can
take them up to be transported perinucleus region without any
further modification [13]. 6-fem (green) labeled AON and
TMRCA-labeled (red) copolymer altogether helped to
visualize the process of endocytosis to C2C12 muscle cells
and the nucleus localization of gene.

II. RESULTS

I. INTRODUCTION

ynthetic vesicles by polyethylene oxide-polybutadiene
(PEO-PBD) or polyethylene oxide-polycaprolactone
(PEO-PCL) have advantages 1) carriers are so inert that it
does not cause inflammation 2) they are so stealthy that they
can circulate in vivo for long time, compared to cationic
carriers and lipid vesicles [1-5]. Programmable release of
encapsulants
by
controlling
the
ratio
of
PEO-PBD/PEO-polyesters would be another advantage [6,
7]. Recently, endosomal release mechanism was elucidated
by computer simulation by F.Ahmed [8].
Antisense oligonucleotides (AON) are being increasingly
used to work around deleterious mutations and/or deletions,
including the dystrophin gene that leads to muscular
dystrophy. The significant advantage of AONs is the ability
to target the gene irrespective of its large size and clinical
applicability as small-molecule based therapy [9]. However,
efficient delivery of AONs in muscles is a great challenge and
much depends on the carriers that provide protection against
degradation, cell specificity and release [10-12].

A. Loading of AON in polymer vesicles “polymersome”
Degradable,
self-porating
polymer
vesicles,
polymersomes, were made with non-degradable and
degradable copolymers. Upon the composition of polymer
membrane, the releasing kinetics from vesicles could be
programmed. Our group described this finding in the prior
report [14]. Briefly, polyethylene oxide-poly butadiene
makes inert, stable bilayer vesicle structures. The PEG-PBD
vesicles are extremely stabilized and do not break over time
[15]. This property was used for encapsulating small
molecules like drug or dyes.
To release their encapsulants, hydrolysable polyethylene
oxide – poly lactic acid or polyethylene oxide – poly
caprolactic acid was mixed to make bilayer polymer vesicles
[14]. Blended polymer vesicles were good for encapsulating
small molecular weight drugs and used for anti-cancer
therapy [8]. In this study, antisense oligonucleotide could be
loaded within polymer vesicles and released over the
programmed time as in Fig. 1.
The releasing kinetics of polymersomes, which were
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TABLE I
PHYSICAL PROPERTIES OF VARIOUS DIBLOCK COPOLYMERS
Copolymer
name

FORMULA
AM –BN

Mn
(kg/mol)

P.D.

wEO

OB2

EO26-BD46

3.6

1.09

0.33

OCL4

EO52-CL44

7.0

1.30

0.29
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long circulation time in vivo [5]. F.Ahmed elucidated the
cyto-toxicity and uptake mechanism of polymersomes [8].
To see the uptake by cells, especially muscle cells,
well-defined muscle cell strips were used. On one separated
muscle cell strips, the interaction of polymersome and cells
could be observed easily, than in the interconnected and
congested multi-nucleated myotubes. The well-defined
patterns made it possible to distinguish between the
polymersomes uptake of and non-specific binding to the
glass surface. C2C12 myotubes grown on well-defined
collagen coated IPN-patterns were used to study the cellular
uptake and kinetics of non-degradable polymer, PEO-PBD.
TMRCA conjugated polymers were mixed in polymersomes
(1mg/ml initial concentration) to be added to the C2C12
myotubes, and muscle cell patterns showed efficient uptake
of polymeric vesicles in 1hr. The inert PEO-PBD vesicles
showed punctated perinuclear localization within the
myotube. Initially, punctuate distributions of internalized
vesicles appeared throughout the cells with gradual
accumulation in the perinuclear regions.

72

Time (hr)

Fig. 1. Encapsulation and release of AON from polymersomes.
(a) Bio-degradable AON (green) loaded vesicles, formed in DMSO-PBS
(15:85) using blended polymers PEO-PBD & PEO-PCL (1:3 w/w , red).
(b) Self-porating vesicles with PEO-PBD & PEO-PCL (1:3) show
sustained release of encapsulants, depending on temperature and pH.
Under slightly acidic conditions typical of endolysosomes, release is
Inset:
accelerated. At 4oC, leakage over days is undetectable.
Polymersomes sized down to 100 nm radiuses by sonication and extrusion
and measured by dynamic light scattering (DLS).

composed of 1:3 ratio of PEO-PBD and PEO-PCL were
tuned for cell culture and animal studies. The releasing
profiles of self-porating vesicles were examined at two
conditions. For physiological conditions at 37 C, pH 7.4, 290
mOsm, for acidic intercellular condition, at pH 5.5 were
measured. The hydrolysis of PEO-PCL was accelerated in
acidic condition, so the releasing time was shortened in the
acidic condition [16]; half time for releasing was 4.5 hrs at
pH 7.4 and 3.4 hrs at pH 5.5. The vesicles were stable at 4 C
for 3 days with no significant release of AON. At low
temperature, hydrolysis is extremely suppressed and
rupturing of vesicle membrane progressed very slowly [17].

AON from non-degradable Psome

a

B. Uptake of non-degradable “ polymersomes” by
C2C12 myotubes
Polymersomes can enter cells without targeting moieties
because they have neutral pH and has poly ethylene glycol
brushes on them. With long polyethylene oxide brushes on
their surface, polymersomes have minimal cyto-toxicities and
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Fig.
2.
In vitro delivery of antisense oligonucleotide using
biodegradable polymer vesicles.
(a) Bright field image showing a single patterned myotube after delivery
with no signs of apoptosis (left). Fluorescent image of delivered AON in
nuclei of the top-layer of the myotube (right). Scale bar is 10 microns (b)
Delivery of AON in nuclei of myotubes grown in petri dish. Overlay
shows the AON transfected nuclei and blue (Hoechst dye) the total
nuclei. (c) Delivery of non-degradable PEO-PBD vesicles. Patterned
myotubes show punctated perinuclear delivery of AON-loaded Polymer

any significant nuclear delivery in myotubes grown in
culture.

1

D. Sub-cellular distribution of AON in nucleus
After uptake of polymersomes by cells, polymersomes
were located near nucleus and antisense was released and
delivered to nucleus. In nucleus localization stage, antisense
behavior was observed with pulse laser, which will exhaust
the antisense fluorescence. High magnification images
showed that antisense were stuck to some peculiar spots, and
looked like antisense was not moving around any more. To
confirm the mobility of antisense in nucleus, a milli-second
pulse laser was shot for photo bleaching. This FRAP study
gave some idea about where antisense is located at after
delivery.
FRAP study found that negatively charged antisense will
be bound to somewhere in nucleus and rest of them will float
freely around. In Figure 3, blue circle is background and pink
circle is the fixed small spot. After few milli-seconds of
photo bleaching, the fluorescence of blue and pink circles
were completed (figure 3.2) the fluorescence intensity went
down. The fluorescence was recovered in the certain time
(figure 3.3). Although the background fluorescence was
recovered almost up to the previous fluorescence level, the
specific spot fluorescence did not come back as much. Only
around 10% intensity levels came back on the pink spot, but
more than 30% intensity levels were recovered in
background, blue spot.
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E. In-vivo delivery of AON-polymersomes in mdx-mice by
intramuscular injections:
Dystrophin-defective mdx mice, which are DMD model
mice, were used for intramuscular delivery, and the

Fig. 3. Intranuclear delivery of fluorescent-AON.
Magnified views of muscle nuclei showed a few discrete spots that are
likely concentrations at nuclear bodies. FRAP was conducted both on and
off of the spots. The latter (red) showed quick and complete recovery of
fluorescence indicating high mobility, whereas the nuclear bodies (blue)
showed little recovery.
AON released from P’some

Nuclei

AON

20 µm

b

AON alone

C. In vitro Release and delivery of AON into C2C12
myotubes
Using degradable polymersome, encapsulated antisense
could be delivered to nuclei. Polymersomes delivered
antisense into cells and after certain time, polymer-shells
were hydrolyzed and encapsulated antisense was released.
The endolysomal delivery mechanism was suggested by
Fariyal Ahmed using MC simulation [8].
In the patterned IPN muscle cell strips, antisense were
delivered into both of top layers and bottom layers. In figure
2.a, the nucleus at upper part is nucleus located at the top
layer and other nucleus is located at the bottom layer.
Congested muscle cells in petri dish were also tested for
delivery. The delivery was fairly comparable to PEI coupled
antisense oligonucleotide. The transfection efficiency of
polymer-loaded AON was comparable to PEI complexed
AON, which was used as control. Free AON did not show

a
Psome

Fig. 4. Intra muscular AON delivery in mdx mice.
(a) Nuclear delivery of AON after release, shown in TA-muscle sections post
12hrs injection. Fluorescent images show red-labeled biodegradable
polymersomes (diffused), blue nuclei (total) and green AON (nuclei). (b)
AON delivery in nuclei after 12hrs post injection of AON alone (no carrier)
as control.
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efficiency of delivery was observed. In 24 hrs of injection
point, mice were sacrificed and TA muscles were pulled out
to snap-freeze to see antisense delivery. The delivery
efficiency was counted as the number of overlaid nuclei by
green fluorescence by antisense and blue-fluorescence by
nuclei. The red fluorescence in polymersomes did not bleed
into green emission range.
Also the efficiency of dystrophin restoration was tested.
Initial experiments were performed in mdx mice 6–8 weeks
(referred to as 6 weeks) of age with a single dose of 3 micro
grams AON loaded in polymer vesicles. Three weeks after
intramuscular injection, immunohistochemistry showed
significant increases in the number of dystrophin-positive
fibers in all skeletal muscles of the treated mice when
compared with age-matched control mdx mice. However, the
number of dystrophin-positive fibers varied between
different areas of individual skeletal muscles and even
between neighboring fibers.
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